Bitter pills: on Court’s intervention, drug pricing
UPSCEditorialsSource: Editorials, Editorial Opinions, Editorial News, The Hindu Opinion | The Hindu
1
Why in News
The Supreme Court has criticised the gap between the price to retailer (PTR) and the maximum retail price (MRP) of certain drugs, including cancer drugs, which in some cases runs up to 1,000%.
2
What is the issue
Since these drugs are not sold over-the-counter, hospitals decide which brand a patient uses; manufacturers inflate the MRP while offering hospitals a low PTR, letting hospitals pocket the difference while patients pay more.
The full analysis is in the app
This page is the summary. The detailed analysis of this story covers:
What is the statusWhat are the challengesWhat measuresWhat lies aheadImportant Data PointsKey conceptsPrevious year questions
Open in Quorum IAS